Patents by Inventor Julian Marius GLÜCK
Julian Marius GLÜCK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11866495Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: GrantFiled: January 29, 2020Date of Patent: January 9, 2024Assignee: Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Jörg Willuda, Mark Trautwein, Uwe Gritzan, Christoph Freiberg, Frank Dittmer, Dorian Schönfeld, Julian Marius Glück, Jessica Pinkert, Eva-Maria Gutierrez, Sven Golfier, Simon Holton, Philip Beckhove, Yingzi Ge
-
Publication number: 20220185901Abstract: The present invention relates to bispecific antibodies binding human ALK-1 and human BMPR-2. Also provided are BsABs which are agonists of ALK-1/BMPR-2 signaling, and BsABs which do not trigger osteogenic signaling. Furthermore, the invention relates to pharmaceutical uses of the BsABs, in particular for the treatment of pulmonary hypertension. Also provided are methods to screen for BsABs for use in the therapy, e.g., of pulmonary hypertension.Type: ApplicationFiled: February 25, 2022Publication date: June 16, 2022Inventors: Ernst WEBER, Joerg MEDING, Florian SOHLER, Julian Marius GLUECK
-
Patent number: 11292846Abstract: Bispecific antibodies binding ALK-1 and BMPR-2 The present invention relates to bispecific antibodies binding human ALK-1 and human BMPR-2. Also provided are BsABs which are agonists of ALK-1/BMPR-2 signaling, and BsABs which do not trigger osteogenic signaling. Furthermore, the invention relates to pharmaceutical uses of the BsABs, in particular for the treatment of pulmonary hypertension. Also provided are methods to screen for BsABs for use in the therapy, e.g. of pulmonary hypertension.Type: GrantFiled: October 25, 2018Date of Patent: April 5, 2022Assignee: Bayer AktiengesellschaftInventors: Ernst Weber, Joerg Meding, Florian Sohler, Julian Marius Glueck
-
Patent number: 11071788Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: GrantFiled: June 20, 2016Date of Patent: July 27, 2021Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Yolanda Cancho Grande, Sven Wittrock, Sandra Berndt, Uwe Gritzan, Jenny Fitting, Beatrix Stelte-Ludwig, Patrick Jones, Christoph Mahlert, Christian Votsmeier, Dorian Schönfeld, Mark Trautwein, Ernst Weber, Nikolaus Pawlowski, Simone Greven, Julian Marius Glück, Stefanie Hammer, Lisa Dietz, Stephan Märsch
-
Publication number: 20200332013Abstract: Bispecific antibodies binding ALK-1 and BMPR-2 The present invention relates to bispecific antibodies binding human ALK-1 and human BMPR-2. Also provided are BsABs which are agonists of ALK-1/BMPR-2 signaling, and BsABs which do not trigger osteogenic signaling. Furthermore, the invention relates to pharmaceutical uses of the BsABs, in particular for the treatment of pulmonary hypertension. Also provided are methods to screen for BsABs for use in the therapy, e.g. of pulmonary hypertension.Type: ApplicationFiled: October 25, 2018Publication date: October 22, 2020Inventors: Ernst Weber, Joerg Meding, Florian Sohler, Julian Marius Glueck
-
Publication number: 20200181261Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: January 29, 2020Publication date: June 11, 2020Applicant: Bayer Pharma AktiengesellschaftInventors: Jörg WILLUDA, Mark TRAUTWEIN, Uwe GRITZAN, Christoph FREIBERG, Frank DITTMER, Dorian SCHÖNFELD, Julian Marius GLÜCK, Jessica PINKERT, Eva-Maria GUTIERREZ, Sven GOLFIER, Simon HOLTON, Philip BECKHOVE, Yingzi GE
-
Publication number: 20200157214Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: January 29, 2020Publication date: May 21, 2020Applicant: Bayer Pharma AktiengesellschaftInventors: Jörg WILLUDA, Mark TRAUTWEIN, Uwe GRITZAN, Christoph FREIBERG, Frank DITTMER, Dorian SCHÖNFELD, Julian Marius GLÜCK, Jessica PINKERT, Eva-Maria GUTIERREZ, Sven GOLFIER, Simon HOLTON, Philip BECKHOVE, Yingzi GE
-
Publication number: 20200138970Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: June 20, 2016Publication date: May 7, 2020Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Sven WITTROCK, Sandra BERNDT, Uwe GRITZAN, Jenny FITTING, Beatrix STELTE-LUDWIG, Patrick JONES, Christoph MAHLERT, Christian VOTSMEIER, Dorian SCHÖNFELD, Mark TRAUTWEIN, Ernst WEBER, Nikolaus PAWLOWSKI, Simone GREVEN, Julian Marius GLÜCK, Stefanie HAMMER, Lisa DIETZ, Stephan MÄRSCH
-
Patent number: 10584167Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: GrantFiled: March 21, 2016Date of Patent: March 10, 2020Assignee: Bayer Pharma AktiengesellschaftInventors: Jörg Willuda, Mark Trautwein, Uwe Gritzan, Christoph Freiberg, Frank Dittmer, Dorian Schönfeld, Julian Marius Glück, Jessica Pinkert, Eva-Maria Gutierrez, Sven Golfier, Simon Holton, Philip Beckhove, Yingzi Ge
-
Publication number: 20180185510Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: June 20, 2016Publication date: July 5, 2018Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Sven WITTROCK, Uwe GRITZAN, Pedro PAZ, Melanie FISCHER, Juergen FRANZ, Julian Marius GLÜCK, Stephan MÄRSCH, Beatrix STELTE-LUDWIG, Christoph MAHLERT, Ernst WEBER, Simone GREVEN, Sandra BERNDT
-
Publication number: 20180162940Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: March 21, 2016Publication date: June 14, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Jörg WILLUDA, Mark TRAUTWEIN, Uwe GRITZAN, Christoph FREIBERG, Frank DITTMER, Dorian SCHÖNFELD, Julian Marius GLÜCK, Jessica PINKERT, Eva-Maria GUTIERREZ, Sven GOLFIER, Simon HOLTON, Philip BECKHOVE, Yingzi GE